Alkermes recently reported positive topline results from its Vibrance-2 phase 2 study of alixorexton in patients with narcolepsy type 2, with the therapy meeting both primary efficacy endpoints and ...
Narcolepsy type 1 is a chronic, rare neurological disease caused by the loss of orexin neurons in the brain. Orexin is a ...
InvestorsHub on MSN
Alkermes Shares Plunge After Mixed Market Reaction to Narcolepsy Drug Trial Results
Alkermes (NASDAQ:ALKS) shares fell 15% after the company released topline results from its Vibrance-2 Phase 2 trial of ...
Alkermes has reported another phase 2 win for its narcolepsy drug candidate, succeeding where Takeda failed to maintain its ...
Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Alixorexton, ...
Switching from a higher to a lower-sodium dose of Xywav led to significant reductions in 24-hour blood pressure for ...
The "United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis" report has been added to ResearchAndMarkets.com's offering ...
The Times Shreveport on MSN
Some generic Adderall medications are being recalled over bottle mislabeling. What to know
Some generic Adderall medications are being recalled over potential impurities and mislabled bottles. Here's what to know about manufacturers.
A mathematical model reveals circadian rhythms' impact on medication efficacy, particularly for neurological conditions like Parkinson’s disease and depression. The model focuses on dopamine reuptake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback